Xenon Pharmaceuticals Reports First Quarter 2015 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Xenon Pharmaceuticals (XENE) Posts Q1 Loss of $0.30/Share
May 12, 2015 4:14 PM EDTXenon Pharmaceuticals (NASDAQ: XENE) reported Q1 EPS of ($0.30), versus the analyst estimate of $0.14. Revenue for the quarter came in at $4 million versus the consensus estimate of $4.65 million.
Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, said, "We continue to make good... More
